Lucid Diagnostics

Lucid Diagnostics is currently developing EsoCheck a rapid, highly accurate, office-based test that utilizes a novel, non-invasive cell-sampling device coupled with proprietary DNA biomarkers to detect Barrett’s Esophagus, precursor to the most common and lethal form of esophageal cancer, caused by acid reflux.

Lucid Diagnostics Inc.
One Grand Central Place
Suite 4600
New York, New York 10165
(212) 949-4319

Medical DevicePharmaceuticals